The LS17-9 monoclonal antibody specifically binds to CD141, also known as thrombomodulin (TM or TRBM) or fetomodulin. CD141 is encoded by Thbd and expressed as a type I transmembrane glycoprotein with an N-terminal C-type lectin domain followed by EGF-like repeats. CD141 is expressed on a variety of cells including endothelial cells, epithelial cells, mesothelial cells, keratinocytes, synovial lining cells, fibroblastic reticular cells, megakaryocytes, dendritic cells, monocytes, macrophages, neutrophils, precursor B cells, and hematopoietic progenitor cells. CD141 is required for normal fetal development. CD141 binds thrombin and this complex can activate Protein C and Thrombin activatable fibrinolysis inhibitor (TAFI), leading to anticoagulant and antifibrinolytic pathway activities.
The antibody was conjugated to BD Horizon BUV737 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 737 nm. BD Horizon Brilliant BUV737 can be excited by the ultraviolet laser (355 nm) and detected with a 740/35 nm filter. Due to the excitation of the acceptor dye by the red laser line, there may be significant spillover into red laser detectors with filters in the 700-720 nm range.